NovaBridge Biosciences announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026. Dr. Gupta succeeds Xi-Yong (Sean) Fu, who resigned from his roles as CEO and director, effective June 30, 2026. Additionally, Emmett T. Cunningham, Jr. M.D., Ph.D., MPH and Sean Cao, Ph.D. resigned from the Board of Directors, effective June 30, 2026, while Mark Hagler resigned as President and will remain as Chief Commercial Officer. NovaBridge Biosciences is a biotechnology company focused on drug discovery and development.

NovaBridge Biosciences dismissed its independent registered public accounting firm, PricewaterhouseCoopers LLP, effective June 16, 2026, and appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP as its new auditor for the fiscal year ending December 31, 2026. The company reported no disagreements with PwC regarding accounting principles or auditing scope, though it noted material weaknesses in information technology general controls for the fiscal years 2024 and 2025. NovaBridge Biosciences is a biotechnology company focused on drug discovery and development.

NovaBridge Biosciences received FDA Fast Track Designation for Givastomig in the treatment of first-line HER2-negative metastatic gastric cancer. NovaBridge Biosciences is a biotechnology company focused on developing therapeutic solutions for oncology-related diseases.